Safety and feasibility of outpatient hematopoietic cell transplantation in pediatric patients during the COVID‐19 pandemic: A single‐center experience
| Autor: | Valentine Jiménez-Antolinez, José Carlos Jaime-Pérez, Perla R. Colunga-Pedraza, Julia E. Colunga-Pedraza, David Gómez-Almaguer, Mariana González-Treviño, Jesús D. Meléndez-Flores, Eugenia M. Ramos-Dávila |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty 2019-20 coronavirus outbreak Adolescent Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Single Center Transplantation Autologous Central Nervous System Neoplasms Cohort Studies Young Adult Outpatients Pandemic medicine Humans Child Letter to the Editor Retrospective Studies Hematopoietic cell business.industry Infant Hematology Transplantation Oncology Child Preschool Pediatrics Perinatology and Child Health Emergency medicine Feasibility Studies Female business |
| Zdroj: | Pediatric Blood & Cancer |
| ISSN: | 1545-5017 1545-5009 |
| DOI: | 10.1002/pbc.29252 |
| Popis: | High-dose chemotherapy with autologous hematopoietic stem cell transplantation (autoHSCT) is a well-established treatment for pediatric central nervous system (CNS) tumors. Given the risks of toxicity and infection, pediatric autoHSCT has been historically performed on hospitalized children. As our practice evolved, some patients were transplanted as outpatients. We performed a retrospective cohort analysis of 37 patients who received 90 transplant procedures (49 outpatient and 41 inpatient) at Children's Hospital Colorado. The most common primary diagnosis was medulloblastoma (51.4%). Of the patients transplanted as outpatients, 69.4% were admitted for fever and neutropenia and had a median time to hospitalization of day +6, with fever and neutropenia being the most common reasons for admission. The median time to neutrophil engraftment was the same in both cohorts, 11 days. Median time to platelet engraftment was 13 days (8-82 days) vs 16 days (8-106 days) (p = 0.0008). At day +100, the transplant-related mortality (TRM) was 0% for both the cohorts. At a median follow-up of 1.7 years, overall survival (OS) for all patients was 66.1% and TRM was 0% for both the cohorts. Outpatient autoHSCT for properly selected children with CNS tumors is safe and effective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text